Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a 12-month low of $0.01 and a 12-month high of $1.99. The stock has a market capitalization of $833,000.00, a P/E ratio of 0.00 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.